Sirolimus-Eluting vs. Paclitaxel-Eluting Stents: A Meta-Analysis

A study of 16 trials suggests that SES are superior to PES, but the whole picture is not yet clear.

To assess the relative efficacy and safety of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES), investigators conducted a meta-analysis of pooled data from 16 randomized head-to-head trials (8695 patients) comparing the stents.

The 30-month probability of reintervention was 9.5% in the SES group and 12.7% in the PES group (hazard ratio, 0.74; P<0.001). The 30-month probability of stent thrombosis was 1.2% in the SES group and 2.6% in the PES group (HR, 0.66; P=0.02); the event curves tended to diverge more widely after the first 12 months. In most trials dual antiplatelet therapy was continued for 6 months, but in several it was continued up to 12 months. Mortality and MI rates were similar in the two groups, with slight tr…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI